<SEC-DOCUMENT>0001564590-18-022422.txt : 20180829
<SEC-HEADER>0001564590-18-022422.hdr.sgml : 20180829
<ACCEPTANCE-DATETIME>20180829083444
ACCESSION NUMBER:		0001564590-18-022422
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180829
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180829
DATE AS OF CHANGE:		20180829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Xenon Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001582313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980661854
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36687
		FILM NUMBER:		181042996

	BUSINESS ADDRESS:	
		STREET 1:		200 - 3650 GILMORE WAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5G 48W
		BUSINESS PHONE:		(604) 484-3300

	MAIL ADDRESS:	
		STREET 1:		200 - 3650 GILMORE WAY
		CITY:			BURNABY
		STATE:			A1
		ZIP:			V5G 48W
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xene-8k_20180829.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
xene-8k_20180829.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="font-size:13pt;"> </font>August 29, 2018</p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">XENON PHARMACEUTICALS INC. </p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:11.25pt;">
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Canada</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-36687</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">98-0661854</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom"  style="width:33.32%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">200-3650 Gilmore Way</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Burnaby, British Columbia, Canada</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-top:0pt;line-height:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">V5G 4W8</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33.32%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.34%;">
<p style="margin-top:0pt;line-height:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33.34%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (604) 484-3300</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-size:9pt;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-bottom:12pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-size:9pt;font-family:'Times New Roman';"><font style="font-size:9pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="text-align:center;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.01</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:10pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Events</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 29, 2018, Xenon Pharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing positive pharmacodynamic data from the Company&#8217;s Phase 1b transcranial magnetic stimulation (TMS) study for its product candidate XEN1101. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A copy of the Company&#8217;s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.&nbsp;&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:10pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:18.58%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit Number</font></p></td>
<td valign="bottom"  style="width:81.42%;">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:18.58%;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:81.42%;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="xene-ex991_7.htm"><font style="text-decoration:underline;">Press Release issued by Xenon Pharmaceuticals Inc. dated August 29, 2018.</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Xenon Pharmaceuticals Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;August 29, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;<font style="font-style:italic;">Ian Mortimer</font></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ian Mortimer</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President &amp; Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>xene-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
xene-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.18157.137 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gde5z2ggwsdk000001.jpg" title="" alt="" style="width:204px;height:27px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#595959;font-size:20pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">NEWS RELEASE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as Measured by TMS-EMG and TMS-EEG</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">XEN1101 Demonstrates Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Historical Ezogabine Data</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">XEN1101 Phase 2 Clinical Trial in Adult Focal Seizures Expected to be Initiated in Fourth Quarter of 2018</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Conference Call Today at 8:30 am ET</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BURNABY, British Columbia,&#160;August 29, 2018 --&#160;Xenon Pharmaceuticals Inc.&#160;(Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced positive data from its XEN1101 Phase 1b transcranial magnetic stimulation (TMS) study<font style="color:#000000;">. XEN1101 is a Kv7 potassium channel opener being developed by Xenon for the treatment of epilepsy. Dr. Isabella Premoli, postdoctoral research fellow at King&#8217;s College London and lead investigator for the XEN1101 Phase 1b TMS study, will be presenting the results </font>in a podium presentation at the 13<sup style="font-size:85%; vertical-align:top">th</sup> European Congress on Epileptology held in Vienna, Austria today.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The completed Phase 1b TMS study was a double-blind, placebo-controlled, randomized cross-over study in 20 healthy male subjects and was initiated based on positive results from a Phase 1a pilot TMS study in 8 healthy subjects, which suggested XEN1101 has an ability to inhibit cortical excitability, an important CNS effect observed with approved anti-epileptic drugs (AEDs). </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Simon Pimstone, Xenon&#8217;s Chief Executive Officer, said, &#8220;Today marks an important step forward in our XEN1101 epilepsy program. We opted to deploy the TMS assay for XEN1101 in order to obtain an early pharmacodynamic, or PD, read-out measuring impact on corticospinal and cortical excitability and to help shape our future development plans. These positive results from our randomized, placebo-controlled TMS study demonstrate that XEN1101 can impact the key EMG output &#8211; the resting motor threshold, or RMT &#8211; in a concentration-dependent manner with statistical significance over placebo at each time point measured, and to a greater extent than historical data for ezogabine, an earlier generation potassium channel modulator. With respect to TMS-EEG, similar to the EMG-RMT, XEN1101 demonstrated an ability to dampen cortical excitability in a concentration-dependent manner with statistical significance over placebo. Overall, these data show robust activity of XEN1101 in the TMS assay and support the advancement of XEN1101 into a Phase 2 clinical trial.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk522271065"></a>Dr. Isabella Premoli, postdoctoral research fellow at King&#8217;s College London and lead investigator for the XEN1101 Phase 1a TMS pilot study and Phase 1b double-blind, placebo-controlled, randomized cross-over study, stated, &#8220;<font style="color:#000000;">The TMS-EMG and TMS-EEG assays have been used previously in healthy subjects to measure cortical excitability of approved AEDs, such as ezogabine, levetiracetam, and lamotrigine. </font>The XEN1101 Phase 1b TMS study has generated very promising results when placed in the context of our experience using TMS to measure effects of approved AEDs. These data indicate we are seeing a robust effect of XEN1101 on corticospinal and cortical excitability. Further, the results appear to be concentration dependent as we are seeing an increased signal in TMS measures as drug concentration levels in the plasma increase over 2-, 4-, and 6-hour time points demonstrating a strong PK-PD effect of XEN1101<font style="font-style:italic;">.</font> Given what we know about the pharmacokinetics of XEN1101, we believe that some of the TMS measurements gathered in this study may potentially underestimate its steady state effect on corticospinal and cortical excitability. These results support the further study of XEN1101 in epilepsy patients.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary of XEN1101 Phase 1b TMS Study Results</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The TMS Phase 1b double-blind, placebo-controlled, randomized cross-over study included 20 healthy male subjects. TMS measurements were taken at 2 and 4 hours for all subjects and, due to a prolonged absorption phase displayed by XEN1101 pharmacokinetics, an additional TMS assessment time-point was added at 6 hours for a subset of subjects. Subjects were randomized initially to either a 20 mg dose of XEN1101 or placebo and then, after a wash-out period, crossed over to the other treatment arm.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">Consistent with </font><font style="font-family:Times New Roman;">the Phase 1a TMS pilot study</font><font style="font-family:Times New Roman;">, XEN1101 reduced corticospinal excitability, as demonstrated by a concentration dependent elevation in </font><font style="font-family:Times New Roman;">RMT, the key TMS-EMG measure</font><font style="font-family:Times New Roman;">. Single </font><font style="font-family:Times New Roman;">20 mg </font><font style="font-family:Times New Roman;">doses of XEN1101 resulted in plasma levels of 15.7 ng/mL, 30.2 ng/mL and 44.4 ng/mL at 2, 4 and 6 hours</font><font style="font-family:Times New Roman;">, respectively</font><font style="font-family:Times New Roman;"> and elevated RMT (as </font><font style="font-family:Times New Roman;">a percentage</font><font style="font-family:Times New Roman;"> of maximum stimulator output) by 1.5&#177;0.4% (p&lt;0.05), 3.0&#177;0.7% (p&lt;0.01) and 4.3&#177;0.8% (p&lt;0.01) compared to time matched placebo changes of 0.4&#177;0.3%, 0.7&#177;0.4% and 0.9&#177;0.3%.&nbsp;&nbsp;This compares to a literature publication of ezogabine (Ossemann et. al) where in a double-blind, placebo-controlled, cross-over study in 15 healthy subjects at a single dose of 400 mg, ezo</font><font style="font-family:Times New Roman;">gabine increased the RMT by 2.4</font><font style="font-family:Times New Roman;">&#177;3.6</font><font style="font-family:Times New Roman;">%</font><font style="font-family:Times New Roman;">. </font><font style="font-weight:bold;font-family:Times New Roman;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">In the TMS-EEG portion of the study, a 20 mg XEN1101 dose statistically significantly modulated TMS-evoked potentials (TEPs) in a manner consistent with reductions in cortical excitability, potentially showing a unique &#8220;fingerprint&#8221; of activity as anticipated based on studies with other AEDs. Relative to time-matched placebo, at peak plasma levels, XEN1101 decreased the amplitude of TEPs measured at 25 ms (N15-P25: 4.5 vs 6.0 &#181;V, p&lt;0.05), 45 ms (N45: -2.3 vs -3.0 &#181;V, p&lt;0.01) and 180 ms (P180: 2.2 vs 3.0 &#181;V, p&lt;0.01) after the TMS pulse. Additional measures of cortical excitability including Global Mean Field Power were similarly impacted by XEN1101.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">XEN1101 was well tolerated with all adverse events (AEs) reported as mild or moderate and reversible. The most common AEs were dizziness and drowsiness, similar to marketed antiepileptic drugs. There were no withdrawals, serious AEs, or deaths.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Update on XEN1101 Phase 1 Clinical Trial and XEN901 Phase 1 Clinical Trial</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to completing both the Phase 1a pilot and Phase 1b TMS studies, Xenon has now completed enrollment in the XEN1101 Phase 1 clinical trial using a powder-in-capsule formulation, which is evaluating the safety, tolerability and pharmacokinetics of both single ascending doses (SAD) and multiple ascending doses (MAD) of XEN1101. The XEN1101 Phase 1 clinical trial included 5 SAD cohorts, a food effect cohort and 3 MAD cohorts of 66 healthy subjects. Interim results presented in May 2018 showed pharmacokinetic data confirming a half-life consistent with once daily dosing, drug exposure levels at doses tested above the EC<sub style="font-size:85%; vertical-align:bottom">50</sub> in preclinical models, and safety data supporting further development of XEN1101. Xenon plans to publish the complete XEN1101 Phase 1 clinical trial results at an upcoming scientific meeting and anticipates initiating a Phase 2 clinical trial evaluating XEN1101 as a treatment for adult focal seizures in the fourth quarter of 2018.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Xenon is also developing XEN901, a potent, highly selective Nav1.6 sodium channel inhibitor, for the treatment of epilepsy. A randomized, double-blind, placebo-controlled Phase 1 clinical trial to evaluate XEN901&#8217;s safety, tolerability and pharmacokinetics in both SAD and MAD cohorts is ongoing, with 6 SAD cohorts, a food effect cohort and 3 MAD cohorts completed and 74 subjects enrolled in the study to date. Interim results presented in May 2018 included favorable pharmacokinetic data that showed dose proportionality and supported twice daily or better dosing, with a predicted elimination half-life of 8 to 11 hours. The multiple dose levels tested yielded drug exposure above the efficacy range for EC<sub style="font-size:85%; vertical-align:bottom">70</sub> in the pre-clinical Maximal Electroshock Seizure model. Based on experience with TMS in the XEN1101 studies, Xenon, along with its collaborators at King College, are exploring the use of the TMS assay in a small subset of a subjects in the ongoing XEN901 Phase 1 clinical trial. Upon completion of the Phase 1 clinical trial, a read-out of the final results is anticipated in the fourth quarter of 2018, and Xenon expects to initiate a Phase 2 clinical trial evaluating XEN901&#8217;s efficacy as a treatment for adult focal seizures or for rare, pediatric forms of epilepsy as soon as feasible thereafter depending on planned discussions with regulatory agencies in the near term.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Pimstone added, &#8220;It is exciting to see the strong momentum generated by our clinical-stage epilepsy programs. Dosing in the XEN1101 Phase 1 clinical trial for the powder-in-capsule formulation is now complete, and pharmacokinetic, safety and tolerability data are consistent with the interim results presented in May 2018. We, along with our scientific steering committee, are planning for the initiation of a Phase 2 clinical trial that would evaluate XEN1101 as a treatment for adult focal seizures, which is expected to be initiated in the fourth quarter of this year. We look forward to presenting the complete XEN1101 Phase 1 results at a scientific meeting by the end of this year. Our XEN901 Phase 1 clinical trial also continues to make progress with dosing in MAD cohorts underway, and, to date, the data are consistent with the promising interim results presented in May 2018.&#8221;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comparisons of XEN1101 and ezogabine are not based on data resulting from head-to-head trials and are not direct comparisons of safety or efficacy. Different protocol designs, trial designs, patient selection and populations, number of patients, trial endpoints, trial objectives and other parameters that are not the same between the relevant trials may cause any comparisons of results from different trials to be unreliable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Conference Call and Webcast Information</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Xenon will host a conference call and webcast today at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to provide a corporate update and discuss the XEN1101 Phase 1b TMS study results. To participate in the call, please dial (855) 779-9075 or (631) 485-4866 for international callers and provide conference ID number 1675798. The webcast will be broadcast live on the &#8220;Investors&#8221; section of Xenon's website at www.xenon-pharma.com and will be available for replay following the call for 30 days.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Xenon Pharmaceuticals Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage, neurology-focused biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing &#8211; both independently and with our collaborators &#8211; a novel product pipeline of central nervous system, or CNS, therapies to address areas of high unmet medical need, such as epilepsy, migraine and pain. For more information, please visit <font style="text-decoration:underline;">www.xenon-pharma.com</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Safe Harbor Statement</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding our expectations regarding the timing of and results from clinical trials and pre-clinical development activities, including those related to XEN901, XEN1101 and our other product candidates, the potential efficacy, safety profile, future development plans, addressable market, regulatory success and commercial potential of XEN901, XEN1101 and our other product candidates, the anticipated timing of IND, or IND equivalent, submissions and the initiation of future clinical trials for XEN901, XEN1101 and our other product candidates, the efficacy of our clinical trial designs, our ability to successfully develop and achieve milestones in the XEN901, XEN1101 and other development programs, the anticipated benefits of the unique mechanisms of action of XEN901 and XEN1101, the design of our clinical trials and anticipated enrollment, the potential for XEN1101 to support once daily dosing, the potential for XEN901 to support twice daily or better dosing, the progress and potential of our other ongoing development programs, and the timing of our public presentation and potential publication of future clinical data. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: promising results in preclinical and early clinical trials may not be replicated in subsequent clinical trials; clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; any of our or our collaborators' product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; the impact of competition; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission and the securities commissions in British Columbia, Alberta and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Xenon&#8221; and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Xenon Investor/Media Contact<font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jodi Regts<br />Phone: 778.999.5634<br />Email: <font style="text-decoration:underline;">investors@xenon-pharma.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gde5z2ggwsdk000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gde5z2ggwsdk000001.jpg
M_]C_X  02D9)1@ ! 0$       #_[@ .061O8F4 9      !_]L 0P $ P,#
M P,$ P,$!@0#! 8'!00$!0<(!@8'!@8("@@)"0D)" H*# P,# P*# P-#0P,
M$1$1$1$4%!04%!04%!04_]L 0P$$!04(!P@/"@H/% X.#A04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@
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M8".%65P76R\;5J7N+15)B,T,NE.;^F2@^L+GS4?ZT83XR_JCA6Q/V%9O:O\
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M!U/T=R/*]O4;H5YL3\Q]!W&U5[$/6]D01$$1!$01$$1!$0105B3]8;K\K?\
M&*C8%F]4SS1Q+F.]??9WYC^T5]6_#]QNEJN5VHF]ZQ:=TJL2G2I+;Q4D+EQ
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M%E_<^AX5(/\ D?K_ '$R_21S%P7<\#W?"-!=VWL1TU:RV_0!#H6E=.[)P3*
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MZ69Q;C[#&"Z93UYK4BI FU0-$+J7"=4D3T ^Z5(<L7,BS3)Q@T<BQ-XWM9K
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MD$/ZSR.%/]#_ )'V$?P:_:3\@A_6>1PI_H?\C[">F1793J>Z]E.L.C=(1O\
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I>E=#_N[O8^VVN2/'^JU_B5JN>$(J^_T_P_\ ^VJUODUJU3>JPX5__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
